Earnings ·
Nanobiotix S.A. reported first-half 2026 financial results and operational updates, posting a net loss of €34.3…
NBTXNanobiotix S.A.
Nanobiotix S.A. reported first-half 2026 financial results and operational updates, posting a net loss of €34.3 million (€0.70 basic loss per share) compared to €5.4 million in the prior year period. Revenue declined to €5.6 million from €26.6 million, primarily due to a €21.2 million one-off non-cash revenue item recorded in H1 2025 following the transfer of NANORAY-312 study sponsorship to Johnson & Johnson. The company holds €110.9 million in cash and cash equivalents as of June 30, 2026, extending its runway into 2029. Clinically, Nanobiotix presented promising early results from a Phase 1 NSCLC study showing a one-year overall survival rate of 70% and acceptable safety data from the J&J-led Phase 2 CONVERGE study in Stage 3 NSCLC. Additionally, the U.S. FDA cleared a protocol amendment for the Phase 3 NANORAY-312 head and neck cancer study to streamline the final analysis. Nanobiotix is a late-stage clinical biotechnology company pioneering physics-based nanotherapeutic approaches for oncology.